IFRXHealthcare · BiotechnologyThe 8 Wall Street analysts covering InflaRx NV hold a median 12-month price target of $8.5 — +306.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores InflaRx NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (83): The shares have been drifting up relative to others.
Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IFRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +306.6% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $4.00 → $6.00 |
| 13 May 2026 | Raymond James | Upgrade | Strong Buy | $7.00 → $9.00 |
| 13 May 2026 | Raymond James | Upgrade | Strong Buy | — |
| 11 May 2026 | Cantor Fitzgerald | Maintains | Overweight | $2.00 → $4.00 |
| 11 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $6.00 → $8.00 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Apr 2026 | Guggenheim | Reiterates | Buy | — |
| 20 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 30 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 10 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 2 Sept 2025 | HC Wainwright & Co. | Assumes | Buy | $6.00 |
| 29 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 8 May 2025 | Oppenheimer | Initiates | Outperform | — |
| 29 Apr 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 26 Mar 2025 | Guggenheim | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IFRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, InflaRx NV returned +42.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 99% of US stocks
Cheaper than 49% of US stocks
Cheaper than 78% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 25% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
InflaRx NV has a market value of $308.0M and an enterprise value of $174.4M.
Revenue in the twelve months to 30 June 2026: −$10K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$39.1M, a 387053.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$23.8M.
Trailing P/E: −3.1×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
InflaRx NV employs 65 people — −$155.4 of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own InflaRx NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
InflaRx N.V. announced it will participate in two investor conferences in September 2026, as detailed in a company release on Aug. 20, 2026. The announcement provides the scheduled dates for these investor engagements.
Why it matters — Investor conference participation offers InflaRx watchers opportunities to hear updates on the company's complement-system therapeutics program.
InflaRx announced its second quarter 2026 financial results and provided a business update. The company reported progress on izicopan for ANCA-associated vasculitis and select renal diseases, initiated a feasibility assessment for a broader European AAV strategy, released new preclinical data, and plans a PK bridging study in China late this year, with cash of €158.4 million expected to fund operations through 2029. A Virtual Capital Markets Day is planned for October 8, 2026.
Why it matters — The update details izicopan's clinical advancement, upcoming proof-of-concept milestones, and a cash runway through 2029, giving InflaRx investors clarity on near-term catalysts and financial staying power.
InflaRx announced it will release its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. The company stated that no conference call is planned for the results.
Why it matters — The announcement informs shareholders of the scheduled release date for the company's quarterly financial performance and operational updates.
The 8 Wall Street analysts covering InflaRx NV have a median 12-month price target of $8.5, with estimates ranging from $3.01 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering InflaRx NV, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InflaRx NV 9 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, InflaRx NV ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +306.6% from the last close, and Ticker Nerd's factor model ranks InflaRx NV 9 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering InflaRx NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IFRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.01 to $14 over the next 12 months.
InflaRx NV returned +42.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways.
The most recent item we track (GlobeNewsWire, 20 Aug 2026): "InflaRx Announces Participation in September Investor Conferences". InflaRx N.V. announced it will participate in two investor conferences in September 2026, as detailed in a company release on Aug. 20, 2026. The announcement provides the scheduled dates for these investor engagements.
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling. Its current pipeline includes vilobelimab, an intravenously administered anti-C5a antibody, and an oral C5aR inhibitor in development for inflammatory indications. InflaRx serves the biotechnology and healthcare sectors, with research and operational activities in Germany and the United States. The company’s work is centered on advancing novel treatments for severe inflammatory conditions where targeted complement inhibition may play an important therapeutic role.
CEO Prof. Niels C. Riedemann M.D., Ph.D. · 65 employees · Germany · https://www.inflarx.de
